CJC Open最新文献

{"title":"From Failure to Positive Result: Turning Aortic Insufficiency in Neocuspidization Procedure Into Excellent Results","authors":"Marien Lenoir MD, PhD , Loïc Mace MD, PhD , Beatrice Desnous MD, PhD , Grégoire Stolpe MD , Jean-Marc El Arid MD","doi":"10.1016/j.cjco.2025.02.013","DOIUrl":"10.1016/j.cjco.2025.02.013","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 675-677"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote Dielectric Sensing Technology in Heart Failure: Correlating Lung-Fluid Volume Shifts with Postural Changes and Dyspnea Severity","authors":"Li-Kai Wang MD, MSc ,&nbsp;Yi-Ju Tsai PhD ,&nbsp;Ying-Chou Wang PhD ,&nbsp;June-Horng Lue PhD ,&nbsp;Chun-Ta Huang MD","doi":"10.1016/j.cjco.2025.03.003","DOIUrl":"10.1016/j.cjco.2025.03.003","url":null,"abstract":"<div><h3>Background</h3><div>Orthopnea, a common symptom in heart failure (HF), arises from elevated pulmonary pressures and interstitial edema due to positional shifts. Remote dielectric sensing (ReDS) offers a noninvasive method to quantify lung-fluid volume. This study evaluated ReDS system measurements in response to posture changes in HF patients, and the correlation of these measurements with dyspnea severity.</div></div><div><h3>Methods</h3><div>This prospective observational study included both healthy volunteers and HF patients. Lung-fluid volume was measured using the ReDS system, with the patients in 3 positions—sitting, supine, and supine with elevated legs. HF patients additionally reported dyspnea levels on a visual analog scale immediately before and after ReDS measurements were made.</div></div><div><h3>Results</h3><div>A total of 86 healthy volunteers and 20 HF patients were included in the study. In healthy volunteers, ReDS values modestly increased when patients changed from a sitting to a supine position (21% vs 22%; <em>P</em> &lt;0.001), and from being supine to supine with raised legs (22% vs 24%; <em>P</em> &lt;0.001). In contrast, HF patients showed significantly higher ReDS values across all positions (29%, 31%, and 34%, respectively), with more pronounced increases between positions compared to those of healthy subjects (<em>P</em> for interaction &lt; 0.001). A strong correlation was observed between ReDS system measurements and dyspnea visual analog scale scores in HF patients following posture changes (Pearson’s <em>r</em> = 0.718, <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The ReDS system effectively quantifies lung-fluid volume changes due to body-position shifts in HF patients. Its measurements correlate well with alterations in dyspnea severity, potentially offering an objective means to monitor HF symptoms. Further studies are needed to validate these findings in a larger cohort and over an extended period.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 606-613"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective","authors":"Nowell Fine MD ,&nbsp;Anique Ducharme MD ,&nbsp;Genevieve Matte MD ,&nbsp;Michelle Mezei MD ,&nbsp;Vera Bril MD ,&nbsp;Diego Delgado MD, MSc","doi":"10.1016/j.cjco.2025.03.002","DOIUrl":"10.1016/j.cjco.2025.03.002","url":null,"abstract":"<div><div>Hereditary amyloid transthyretin variant (ATTRv) amyloidosis is a rare, life-threatening disease, characterized by the deposition of aggregated transthyretin (TTR) protein in multiple organs and tissues. Diagnosis is often delayed due to its heterogeneity in presentation, which includes a wide range of cardiac and/or neurologic symptoms. Thus, awareness of ATTRv amyloidosis across multiple specialties is needed for its early diagnosis and management. This paper provides a review surrounding the diagnosis and management of mixed phenotype ATTRv amyloidosis, addressed through 3 clinical questions. This paper discusses: (i) the need for patients with ATTRv amyloidosis to be screened for mixed cardiac and neurologic phenotypes through early multidisciplinary referral; (ii) the therapeutic landscape for ATTRv amyloidosis in Canada, with emphasis on the need for prompt therapy selection and initiation, based on multidisciplinary collaboration; and (iii) how disease can be monitored pre- and post-treatment. Case studies are provided to illustrate how the available evidence impacts practice.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 5","pages":"Pages 614-627"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CArdiovasculaR Outcomes Based Upon EjectIon Systolic TimE in Patients With ST Elevation Myocardial Infarction (ARISE-STEMI) Study","authors":"Tyler Szun BSc ,&nbsp;Alexander Zaremba BSc ,&nbsp;Aleksander Dokollari MD, PhD ,&nbsp;Azin Khafipour MSc ,&nbsp;Hilary Bews MD, FRCPC ,&nbsp;Seth Cheung ,&nbsp;James W. Tam MD, FRCPC ,&nbsp;Shuangbo Liu MD, FRCPC ,&nbsp;Derek So MD, FRCPC ,&nbsp;Sean Van Diepen MD, FMSc ,&nbsp;Ashish H. Shah MD, MD-Research, FRCP","doi":"10.1016/j.cjco.2024.11.014","DOIUrl":"10.1016/j.cjco.2024.11.014","url":null,"abstract":"<div><h3>Background</h3><div>Despite improvements in revascularization, systems of care, and secondary prevention therapies, 30-day mortality rates in patients presenting with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) remains 4% to 6%. This study aims to investigate the utility of the ejection systolic time (EST) and ejection systolic period (ESP) in identifying high-risk STEMI patients.</div></div><div><h3>Methods</h3><div>In this retrospective study, consecutive patients with STEMI undergoing PPCI at a tertiary cardiac center between January 2020 and October 2021 were included. EST and ESP were calculated on the MacLab. Univariable and multivariable Cox regression analysis were used to identify risk predictors. The primary outcome was mortality at 30 days.</div></div><div><h3>Results</h3><div>Six hundred forty-one STEMI patients (mean age: 64.4 ± 13.2 years; 182/641 [28.4%] female patients) were recruited. Within 30 days of presentation, 32 patients (5.0%) died, and they were more frequently older, female, and had higher rates of previous stroke, chronic kidney disease, and dialysis use. Patients dying within 30 days had lower EST (0.20 ± 0.04 vs 0.24 ± 0.04 seconds/beat; <em>P</em> &lt; 0.0001) and ESP (17.64 ± 2.66 vs 19.29 ± 2.74 seconds/min; <em>P</em> = 0.004). After multivariable modeling, only EST was a significant predictor of early (&lt;30 days) mortality (hazard ratio 4.5, 95% confidence interval 1.7-12.1; <em>P</em> = 0.003), prolonged in-hospital stay (&gt;4 days), diuretic use, new diagnosis of heart failure, need for intubation or ventilation, and inotrope and/or vasopressor use during the index hospital admission. ESP and EST were not associated with the mortality between 30 days and 1 year.</div></div><div><h3>Conclusions</h3><div>A lower EST was associated with mortality at 30 days and in-hospital adverse outcomes. EST may serve as a useful hemodynamic marker to risk-stratify STEMI patients.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 516-524"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Misclassification of Hypertension Status According to Office Blood Pressure vs 24-Hour Ambulatory Blood Pressure Monitoring","authors":"Gregory L. Hundemer MD, MPH ,&nbsp;Ayub Akbari MD, MSc ,&nbsp;Amos Buh PhD ,&nbsp;Nandini Biyani BSc ,&nbsp;Shaafi Mahbub BSc ,&nbsp;Maria Salman BSc ,&nbsp;Pierre A. Brown MD ,&nbsp;Greg A. Knoll MD, MSc ,&nbsp;Manish M. Sood MD, MSc ,&nbsp;Swapnil Hiremath MD, MPH ,&nbsp;Marcel Ruzicka MD, PhD","doi":"10.1016/j.cjco.2025.01.007","DOIUrl":"10.1016/j.cjco.2025.01.007","url":null,"abstract":"<div><h3>Background</h3><div>Ambulatory blood pressure monitoring (ABPM) is the gold standard for establishing the diagnosis of hypertension yet remains underused in Canada. There remains a scarcity of Canadian data surrounding how commonly misclassification of hypertension phenotypes occurs without regular use of ABPM.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 964 consecutive adult patients referred to the Ottawa Hospital Hypertension Clinic who underwent same-day ABPM and automated office-based blood pressure measurement (AOBPM) between 2019 and 2023. The proportion of hypertension status misclassification was determined by comparing ABPM and AOBPM values. White coat hypertension (if on no antihypertensive medication) or white coat effect (if on antihypertensive medication) was defined as AOBPM ≥140/90 mm Hg but mean 24-hour ABPM &lt;130/80 mm Hg. Masked hypertension (if on no antihypertensive medication) or masked uncontrolled hypertension (if on antihypertensive medication) was defined as AOBPM &lt;140/90 mm Hg but mean 24-hour ABPM ≥130/80 mm Hg.</div></div><div><h3>Results</h3><div>The mean (SD) age was 60 (16) years, and 46% of the patients were female. Among 296 patients with normotension or controlled hypertension based on ABPM, 146 (49%) met criteria for white coat hypertension (n = 21) or white coat effect (n = 125). Among 668 patients with uncontrolled hypertension based on ABPM, 364 (54%) met criteria for masked hypertension (n = 65) or masked uncontrolled hypertension (n = 299).</div></div><div><h3>Conclusions</h3><div>The hypertension status of approximately 50% of patients was misclassified by AOBPM vs ABPM. Broader use of ABPM in Canada will improve hypertension awareness, treatment, and control rates.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 508-515"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling Heart Failure Phenotypes: A Systematic Review and Meta-analysis of Peak Oxygen Uptake and Its Determinants","authors":"Corey R. Tomczak PhD ,&nbsp;Stephen J. Foulkes PhD ,&nbsp;Christopher Weinkauf BSc ,&nbsp;Devyn Walesiak BSc ,&nbsp;Jing Wang PhD ,&nbsp;Veronika Schmid MSc ,&nbsp;Sarah Paterson BSc ,&nbsp;Wesley J. Tucker PhD ,&nbsp;Michael D. Nelson PhD ,&nbsp;Simon Wernhart MD, PhD ,&nbsp;Jan Vontobel MD ,&nbsp;David Niederseer MD, PhD ,&nbsp;Mark J. Haykowsky PhD","doi":"10.1016/j.cjco.2025.01.012","DOIUrl":"10.1016/j.cjco.2025.01.012","url":null,"abstract":"<div><h3>Background</h3><div>Understanding the impact of heart failure (HF) phenotype on peak oxygen uptake (peak <span><math><mrow><mover><mi>V</mi><mo>˙</mo></mover></mrow></math></span>O₂) is essential for advancing personalized treatment strategies and enhancing patient outcomes. Therefore, we conducted a systematic review and meta-analysis of the evidence examining differences in peak <span><math><mrow><mover><mi>V</mi><mo>˙</mo></mover></mrow></math></span>O₂ (primary objective) and its determinants (secondary objectives) between patients with HF with reduced (HFrEF) or preserved ejection fraction (HFpEF).</div></div><div><h3>Methods</h3><div>Studies comparing peak <span><math><mrow><mover><mi>V</mi><mo>˙</mo></mover></mrow></math></span>O₂ in HFrEF vs HFpEF were found through PubMed (1967-2024), Scopus (1981-2024), and Web of Science (1985-2024). Data extraction and methodologic quality assessment were completed by 2 independent coders. Differences between HFrEF and HFpEF were compared using weighted mean difference (WMD) and 95% confidence intervals (95% CIs) derived from random effects meta-analysis.</div></div><div><h3>Results</h3><div>After screening 3107 articles, 25 unique studies were included in the analysis for the primary outcome (HFrEF n = 3783; HFpEF n = 3279). Peak <span><math><mrow><mover><mi>V</mi><mo>˙</mo></mover></mrow></math></span>O₂ (WMD: –1.6 mL/kg/min, 95% CI: –2.3 to –0.8 mL/kg/min), and peak exercise measures of cardiac output (WMD: –1.1 L/min, 95% CI: –2.1 to –0.2 L/min), stroke volume (WMD: –10.1 mL, 95% CI: –16.6 to –3.7 mL), heart rate (WMD: –4 bpm, 95% CI: –6 to –2 bpm), and left ventricular ejection fraction (WMD: –28.2%, 95% CI: –32.6% to –23.8%) were significantly lower while peak exercise arterial-venous oxygen difference was significantly higher in HFrEF compared with HFpEF (2.3 mL/dL, 95% CI: 1.6-2.9 mL/dL).</div></div><div><h3>Conclusions</h3><div>Our findings highlight distinct physiological impairments along the oxygen cascade in HFrEF compared with HFpEF, with direct implications for the management and treatment strategies of these HF subtypes.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 367-379"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Value of the Triglyceride-Glucose and Fibrosis-4 Indices in Patients Undergoing Coronary Angiography: A Retrospective Cohort Analysis","authors":"Amir Aker MD ,&nbsp;Tom Tarchitzky BsC ,&nbsp;Yuval Avidan MD ,&nbsp;Barak Zafrir MD","doi":"10.1016/j.cjco.2025.01.005","DOIUrl":"10.1016/j.cjco.2025.01.005","url":null,"abstract":"<div><h3>Background</h3><div>The triglyceride-glucose (TYG) index, which reflects insulin resistance, and the fibrosis-4 (FIB-4) index, a measure of liver fibrosis, are noninvasive laboratory-based indicators associated with cardiometabolic risk.</div></div><div><h3>Methods</h3><div>We performed a retrospective analysis of 12,165 patients who underwent coronary angiography, to investigate the association of the TYG and FIB-4 indices with the occurrence of myocardial infarction, stroke, or all-cause death (major cardiovascular events [MACE]), using multivariate Cox proportional hazards models.</div></div><div><h3>Results</h3><div>The mean age of the study population was 65 ± 10 years; 63% presented with acute coronary syndrome. During a median follow-up period of 6.1 years, the first MACE occurred in 4174 patients. Compared to the TYG index ≤ 50th percentile (≤ 8.81), the multivariable adjusted hazard ratio (95% confidence interval) for MACE was 1.17 (1.10-1.45), 1.32 (1.23-1.43), and 1.72 (1.55-1.99) for TYG index levels ≥ 50th (&gt; 8.81), ≥ 75th (&gt; 9.23), and ≥ 90th (9.66) percentiles, respectively. FIB-4 index levels of 1.3-2.67 and &gt; 2.67 were associated with an adjusted hazard ratio of 1.19 (1.11-1.27) and 1.67 (1.51-1.87), respectively, compared to FIB-4 index levels of &lt; 1.3. Regarding the risk of developing MACE, no significant interaction was detected between TYG or FIB-4 index levels and the presence of diabetes or obesity. In a combined model of both predictive measures, a gradual increase in the incidence rate of MACE was observed, ranging from 3.93 (TYG index ≤ 8.81; FIB-4 index &lt; 1.3) to 8.56 (TYG index &gt; 9.23; FIB-4 index &gt; 2.67) events per 100 patient-years.</div></div><div><h3>Conclusions</h3><div>The TYG and FIB-4 indices, both individually and when concomitantly elevated, were independently associated with an increased risk of developing MACE in patients undergoing coronary angiography. ,. These simple-to-calculate, noninvasive metabolic biomarkers may aid in the prediction of cardiovascular diseases.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 465-472"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeated Transcatheter Valve Interventions After Surgical Mitral Valve Replacement: A 20-Year Journey Avoiding Surgical Redo","authors":"Christos Papageorgiou MD ,&nbsp;Marco B. Ancona MD ,&nbsp;Ciro Vella MD ,&nbsp;Vittorio Romano RT ,&nbsp;Luca A. Ferri MD ,&nbsp;Filippo Russo MD ,&nbsp;Barbara Bellini MD ,&nbsp;Giulia Ghizzoni MD ,&nbsp;Greca Zanda MD ,&nbsp;Domitilla Gentile MD ,&nbsp;Francesca Napoli MD ,&nbsp;Antonio Esposito MD ,&nbsp;Eustachio Agricola MD ,&nbsp;Alaide Chieffo MD ,&nbsp;Matteo Montorfano MD","doi":"10.1016/j.cjco.2025.01.020","DOIUrl":"10.1016/j.cjco.2025.01.020","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 489-492"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Socioeconomic Status Is Associated with Reduced Access to Natriuretic Peptide Testing in the Outpatient Setting: A Population-based Evaluation","authors":"Ismail R. Raslan MD, MSc ,&nbsp;Anna Chu MHSc ,&nbsp;Peter C. Austin PhD ,&nbsp;Xuesong Wang MSc ,&nbsp;David Bobrowski MD ,&nbsp;Barbara S. Doumouras MD ,&nbsp;Joseph J. Lee BSc ,&nbsp;Candace D. McNaughton MD, PhD ,&nbsp;Peter A. Kavsak PhD ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Heather J. Ross MD, MHSc ,&nbsp;Douglas S. Lee MD, PhD","doi":"10.1016/j.cjco.2025.01.002","DOIUrl":"10.1016/j.cjco.2025.01.002","url":null,"abstract":"<div><h3>Background</h3><div>Tests of natriuretic peptide (NP) concentrations are guideline-recommended for diagnosis and prognostication in heart failure (HF). Although NP testing is available at some hospitals, outpatient access has been limited to those who can pay out-of-pocket. We investigated whether residents who have lower socioeconomic status have differential access to NP testing.</div></div><div><h3>Methods</h3><div>Using a case-control design, we compared patients who had NP tests with age-matched patients undergoing non-NP blood tests (January 2015-June 2020), performed in the outpatient or acute hospital setting. The association of socioeconomic status measures (eg, deprivation quintile) with receipt of NP testing was assessed using conditional logistic regression, adjusted for sex, test location, and comorbidities, and was stratified by incidence of prior HF.</div></div><div><h3>Results</h3><div>Among 96,919 patients without prior HF (median age, 72 years; 50% female) who underwent NP testing, the majority of tests (66.6%) were performed in an acute hospital setting rather than in an outpatient clinic. Residents of more-deprived neighbourhoods had a higher incidence of HF (<em>P</em> &lt; 0.001), but they were more likely to undergo NP testing in an acute care setting (odds ratio [OR] for most- vs least-deprived, 1.269; 95% confidence interval [CI], 1.104-1.216) and less likely to undergo testing as outpatients (OR, 0.807; 95% CI, 0.764-0.853 vs least-deprived; all <em>P</em> &lt; 0.001). Among 70,362 matched patients with known HF (median aged, 78 years; 45% female), outpatient NP testing was also less likely to be performed among patients living in the most-deprived neighbourhoods (OR, 0.723; 95% CI, 0.677-0.772; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Although those of lower socioeconomic status exhibit a higher risk of incident HF, they had less NP testing performed in outpatient settings, and more testing performed in resource-intense acute-care settings.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 390-401"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy-Induced Hypertension and Atherosclerotic Cardiovascular Disease Risk Score in China","authors":"Honghong He MM ,&nbsp;Junyan Sun MM ,&nbsp;Hongqiu Huo MB ,&nbsp;Yanxiu Wang MD ,&nbsp;Yuntao Wu MM ,&nbsp;Suhua Chen MB ,&nbsp;Yangyang Wang MM ,&nbsp;Xiaoming Zheng MD ,&nbsp;Haiyan Zhao MD","doi":"10.1016/j.cjco.2025.01.006","DOIUrl":"10.1016/j.cjco.2025.01.006","url":null,"abstract":"<div><h3>Background</h3><div>Pregnancy-induced hypertension (PIH) poses a significant threat to maternal health. This study aims to explore the association between PIH and the risk of atherosclerotic cardiovascular disease (ASCVD).</div></div><div><h3>Methods</h3><div>The cohort comprised 1947 pregnant women delivering a single child between 2004 and 2020 in the Kailuan study. Participants, categorized into PIH and non-PIH (NPIH) groups based on PIH history, completed questionnaires and underwent physical examinations and laboratory assessments within 2 years after delivery. Predicted ASCVD risks used the Atherosclerotic Cardiovascular Disease Risk in China (China-PAR) model, distinguishing lifetime ASCVD risk as \"low\" (&lt;32.8%) and \"high\" (≥32.8%). χ² tests and logistic regression were used to investigate the association between PIH and high lifetime risk China-PAR categories.</div></div><div><h3>Results</h3><div>Overall, 6.17% of the PIH group had high lifetime risk, compared with 0.96% in the NPIH group (χ² 29.59, <em>P</em> &lt; 0.001). After adjusting for confounders, PIH was independently associated with high-risk China-PAR categories, with the PIH group having a 5.03 times higher probability than the NPIH group (95% CI 2.20-11.51, <em>P</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>Pregnancy-induced hypertension was associated with increased lifetime risk of ASCVD.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 4","pages":"Pages 435-440"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}